Molecular dynamics simulations reveal LL-37 inhibits hIAPP amyloid aggregation by binding monomers, oligomers, and fibrils through hydrophobic and pi-pi interactions at amyloidogenic regions, blocking self-association and fibril elongation.
Triple-level amyloid inhibitionLL-37 blocks hIAPP aggregation at three stages: monomer self-association, oligomer growth, and fibril elongation—linking innate immunity with anti-amyloid defense
What the researchers found
LL-37 binds hIAPP monomers, oligomers, and fibrils. Mechanism: hydrophobic + pi-pi interactions at amyloidogenic regions. Monomer/oligomer: LL-37 N/C-terminal residues prevent self-association. Fibrils: geometric incompatibility blocks elongation. Links infection defense with amyloid disease.
Why it matters
Type 2 diabetes involves amyloid deposits in the pancreas that kill beta-cells. Understanding how LL-37 prevents this aggregation could lead to dual-function therapeutics that fight both infections and amyloid diseases.
How the study worked
All-atom discrete molecular dynamics (DMD) simulations of LL-37 with hIAPP monomers, oligomers, and fibril seeds. Interaction analysis, conformational dynamics, key residue identification.
What this study cannot tell us
Computational study only—no experimental validation of proposed mechanism. Simulated conditions may not replicate physiological concentrations. All-atom DMD has inherent approximations.
How to read the evidence
Computational mechanistic study using advanced molecular dynamics. Strong theoretical framework needing experimental validation.
When this study was published
Published in 2025.
The bigger picture
The connection between infections and amyloid diseases is increasingly recognized. LL-37's ability to prevent both pathogen growth and amyloid aggregation suggests the innate immune system evolved dual defense mechanisms.
Questions still open
- Can LL-37-inspired peptides be designed as anti-amyloid drugs?
- Does LL-37 deficiency correlate with increased islet amyloid in T2DM?
- Would LL-37 also inhibit Aβ aggregation in Alzheimer's through similar mechanisms?
Common questions
How does LL-37 prevent diabetes-related protein clumping?
Could this lead to new diabetes treatments?
Read the original research
Unveiling the inhibition mechanism of host-defense peptide cathelicidin LL-37 on the amyloid aggregation of the human islet amyloid polypeptide.
Nanoscale, 17(9), 5116-5127
Citation
Tang, Huayuan. (2025). Unveiling the inhibition mechanism of host-defense peptide cathelicidin LL-37 on the amyloid aggregation of the human islet amyloid polypeptide.. Nanoscale, 17(9), 5116-5127. https://doi.org/10.1039/d4nr05075d